Six of seven patients with Raynaud's disease were subjectively benefited by the administration of "fine-particle" griseofulvin in dosages of 500 or 1,000 mg daily. Objective improvement was determined by measuring the digital temperature response following a one-minute exposure of the digit to stirred ice water maintained at 0 C. The temperature curves following griseofulvin therapy showed a much more rapid recovery toward normal when compared to the original baseline curves, and, in most instances, approached the mean control curve of 14 normal subjects.